Ardelyx (NASDAQ:ARDX) CFO Susan Hohenleitner Sells 2,033 Shares

Ardelyx, Inc. (NASDAQ:ARDX) CFO Susan Hohenleitner sold 2,033 shares of the company’s stock in a transaction dated Friday, February 20th. The shares were sold at an average price of $5.85, for a total transaction of $11,893.05. Following the completion of the transaction, the chief financial officer owned 230,533 shares in the company, valued at approximately $1,348,618.05. This trade represents a 0.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Ardelyx Stock Performance

NASDAQ:ARDX opened at $5.75 on Tuesday. The company has a debt-to-equity ratio of 1.21, a current ratio of 4.31 and a quick ratio of 4.11. The firm has a market cap of $1.40 billion, a PE ratio of -23.00 and a beta of 0.57. The firm has a 50 day simple moving average of $6.76 and a 200-day simple moving average of $6.13. Ardelyx, Inc. has a 1-year low of $3.21 and a 1-year high of $8.40.

Ardelyx (NASDAQ:ARDX) last announced its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.03). The firm had revenue of $125.22 million for the quarter, compared to analyst estimates of $118.04 million. Ardelyx had a negative return on equity of 40.63% and a negative net margin of 15.12%.The firm’s revenue was up 7.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.02 EPS. On average, equities analysts expect that Ardelyx, Inc. will post -0.18 EPS for the current year.

Ardelyx News Roundup

Here are the key news stories impacting Ardelyx this week:

• Positive Sentiment: Director David M. Mott purchased 333,333 shares (~$1.95M) at about $5.84, increasing his stake by ~11.2% — a strong insider vote of confidence that can support the stock. SEC Filing: Director Purchase
• Positive Sentiment: Wedbush reaffirmed an “outperform” rating and set a $19 price target (large upside vs. current levels), which can attract buyers and boost sentiment. Wedbush Note via Benzinga
• Positive Sentiment: Other firms reiterated bullish views (BTIG buy rating; HC Wainwright optimistic on FY2026 earnings), reinforcing analyst support that can sustain buying interest. BTIG Reiteration HC Wainwright Note
• Neutral Sentiment: Quarterly revenue beat estimates ($125.2M vs. $118.0M) and year-over-year revenue growth of ~7.8% — a constructive fundamental datapoint, though offset by an EPS miss. (Earnings release was on Feb 19.)
• Negative Sentiment: Earnings EPS missed expectations (reported a loss vs. small expected profit), which triggered a sell-off (shares were reported down ~10.4% after the earnings release). EPS misses typically pressure sentiment and can lead to continued volatility. Earnings Reaction
• Negative Sentiment: Multiple insiders — including the CEO, CFO and several executives — sold shares on Feb 20 (notably the CEO sold ~45,982 shares). Clustered insider selling can be read as profit-taking or reduced insider conviction and may weigh on sentiment. (These sales occurred near $5.85.) SEC Filing: CEO Sale

Institutional Trading of Ardelyx

A number of institutional investors and hedge funds have recently bought and sold shares of ARDX. Invesco Ltd. raised its holdings in Ardelyx by 23.1% in the fourth quarter. Invesco Ltd. now owns 317,410 shares of the biopharmaceutical company’s stock valued at $1,851,000 after buying an additional 59,597 shares during the period. Mercer Global Advisors Inc. ADV lifted its holdings in shares of Ardelyx by 4.7% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 38,512 shares of the biopharmaceutical company’s stock valued at $225,000 after acquiring an additional 1,722 shares in the last quarter. Mackenzie Financial Corp boosted its position in Ardelyx by 12.8% during the 4th quarter. Mackenzie Financial Corp now owns 199,550 shares of the biopharmaceutical company’s stock worth $1,155,000 after purchasing an additional 22,715 shares during the period. NewEdge Advisors LLC increased its holdings in Ardelyx by 1,690.9% in the 4th quarter. NewEdge Advisors LLC now owns 17,909 shares of the biopharmaceutical company’s stock valued at $104,000 after purchasing an additional 16,909 shares in the last quarter. Finally, XTX Topco Ltd purchased a new position in Ardelyx in the fourth quarter valued at about $698,000. Institutional investors and hedge funds own 58.92% of the company’s stock.

Analysts Set New Price Targets

ARDX has been the topic of several recent analyst reports. HC Wainwright increased their target price on Ardelyx from $10.00 to $18.00 and gave the stock a “buy” rating in a research report on Friday. Raymond James Financial reiterated a “strong-buy” rating and set a $19.00 price objective on shares of Ardelyx in a report on Thursday, January 8th. TD Cowen restated a “buy” rating on shares of Ardelyx in a report on Thursday, January 29th. BTIG Research reaffirmed a “buy” rating and set a $17.00 price target on shares of Ardelyx in a research report on Friday. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $15.00 price target on shares of Ardelyx in a research note on Tuesday, January 27th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Ardelyx presently has an average rating of “Buy” and an average target price of $15.09.

About Ardelyx

Ardelyx, Inc (NASDAQ: ARDX) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.